Who are Lamictal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Horizant, OXCARBAZEPINE, Gabitril, Cerebyx, Felbatol, Depakene.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lamotrigine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lamictal — Competitive Intelligence Brief

Lamictal (lamotrigine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-epileptic Agent [EPC]. Area: Neuroscience.

marketed Anti-epileptic Agent [EPC] 5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha Neuroscience Live · refreshed every 30 min

Target snapshot

Lamictal (lamotrigine) — GSK.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lamictal TARGET	lamotrigine	GSK	marketed	Anti-epileptic Agent [EPC]	5-hydroxytryptamine receptor 3A, Sigma non-opioid intracellular receptor 1, Sodium channel protein type 1 subunit alpha
Horizant	GABAPENTIN ENACARBIL	Azurity	marketed	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	2011-01-01
OXCARBAZEPINE	OXCARBAZEPINE		marketed	Anti-epileptic Agent [EPC]		2000-01-01
Gabitril	TIAGABINE	Cephalon	marketed	Anti-epileptic Agent	Sodium- and chloride-dependent GABA transporter 1	1997-01-01
Cerebyx	FOSPHENYTOIN	Pfizer	marketed	Anti-epileptic Agent	Sodium channel protein type 5 subunit alpha	1996-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
Depakene	valproic acid	Generic (originally Abbott/AbbVie)	marketed	Anti-epileptic Agent [EPC]	Alcohol dehydrogenase [NADP(+)], Histone deacetylase 1, Histone deacetylase 2	1978-02-28

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-01-07 — Lamictal · 8637512 · Formulation · US
2040-05-29 — Lamictal · 11596634 · Method of Use · US
2040-05-29 — Lamictal · 11612566 · Method of Use · US

Sponsor landscape (Anti-epileptic Agent [EPC] class)

· 2 drugs in this class
Bausch Health · 1 drug in this class
GSK · 1 drug in this class
Generic (originally Abbott/AbbVie) · 1 drug in this class
Mylan Speciality Lp · 1 drug in this class
Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lamictal — Competitive Intelligence Brief. https://druglandscape.com/ci/lamotrigine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab